ipilimumab,nivolumab
bms
[]
#gi23 continues to impress and guide us with an update on checkmate 649 which showed a continued improvement in mos with nivolumab added to folfox. 21% long term survivors in the cps&gt;=5 group....that's awesome 
GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues